Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Bought by Man Group plc

Man Group plc raised its position in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 34.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,338 shares of the company’s stock after purchasing an additional 15,059 shares during the quarter. Man Group plc owned about 0.36% of Sensus Healthcare worth $411,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in Sensus Healthcare in the 4th quarter valued at about $27,000. Barclays PLC acquired a new position in Sensus Healthcare in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets acquired a new position in Sensus Healthcare in the 4th quarter valued at about $47,000. IFP Advisors Inc acquired a new position in Sensus Healthcare in the 4th quarter valued at about $95,000. Finally, NewEdge Advisors LLC acquired a new position in Sensus Healthcare in the 4th quarter valued at about $109,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SRTS has been the topic of several recent analyst reports. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Maxim Group decreased their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Sensus Healthcare in a report on Friday, April 4th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Sensus Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Sensus Healthcare Stock Up 0.2%

Shares of SRTS opened at $4.69 on Tuesday. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The firm’s 50 day moving average price is $4.61 and its 200 day moving average price is $6.04. The company has a market cap of $77.13 million, a P/E ratio of 11.73 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The business had revenue of $8.34 million for the quarter, compared to analysts’ expectations of $7.23 million. Research analysts forecast that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.